We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cephalon has filed a new drug application for a drug that would help cancer patients get fast relief for "breakthrough pain," a temporary but often excruciating burst of pain that breaks through the comfort provided by medication.
AVAX Technologies has filed an investigational new drug application with the FDA for a Phase I/II clinical trial treating patients with Stage I and II non-small cell lung cancer.
Hana Biosciences has initiated a Phase I IPdR clinical trial in colorectal, gastric, pancreatic and liver cancers. The objectives of this clinical trial are to establish the safety, dose and preliminary efficacy of IPdR in combination with radiation therapy.
CytRx has announced interim results from a Phase I clinical trial indicating that a novel HIV DNA + protein vaccine was well tolerated, stimulated immune T-cells that potentially can attack AIDS virus-infected cells, and produced potent antibody responses with neutralizing activity against multiple HIV viral strains.
MediciNova has announced the completion of patient enrollment in a Phase II clinical study with MN-001 for the treatment of asthma. MN-001, which is orally administered, is a leukotriene receptor antagonist.
BioAlliance Pharma has announced that its investigational new drug application to conduct a pivotal Phase III clinical trial of the antifungal agent miconazole Lauriad has been accepted by the FDA.
Sanofi-aventis has announced that the FDA has approved Ambien CR CIV, a new extended-release formulation of the prescription sleep aid, Ambien CIV, for the treatment of insomnia.